Brandon Huffman

Dr. Brandon Huffman, MD is a Clinical Investigator at the Hale Family Center for Pancreatic Cancer Research and a member of the DF/HCC Gastrointestinal Oncology Disease Center. He is affiliated with the Department of Medical Oncology at the Dana-Farber Cancer Institute and holds the academic rank of Instructor in Medicine at Harvard Medical School.

Education and Training:

• Undergraduate and Medical Degrees: University of Missouri, Columbia, MO
• Internal Medicine Residency: Mayo Clinic, Rochester, MN (served as Chief Medical Resident)
• Medical Oncology Fellowship: Dana-Farber Cancer Institute / Mass General Brigham (served as Chief Fellow)

Dr. Huffman is a translational and clinical researcher focused on advancing novel therapeutics for pancreatic cancer. His work emphasizes the design and execution of innovative clinical trials, particularly in second-line treatment settings. He has led pivotal studies involving gemcitabine and nab-paclitaxel after FOLFIRINOX failure and is exploring targeted agents like WEE1 and CHK1 inhibitors in combination with chemotherapy. His research bridges preclinical insights with clinical applications, aiming to improve outcomes in pancreatic adenocarcinoma.

His recent publications demonstrate a strong focus on targeted therapies, DNA repair inhibition, and immunotherapeutic combinations in pancreatic cancer. These works reflect a trajectory toward biomarker-driven and mechanism-based clinical trial design.

Scientific Awards and Honors:

Dr. Huffman serves as Principal Investigator on clinical trials and collaborates closely with laboratory scientists at the Hale Center. While no formal advisees are listed, his leadership roles as chief resident and chief fellow, along with his PI status, indicate active mentorship and grant-supported research. He is embedded in a multidisciplinary team advancing pancreatic cancer therapeutics.